Product image of Matrifen (Fentanyl) supplied by GNH India

Matrifen

Active Ingredient:
Fentanyl
Origin:
EU

Matrifen (Fentanyl)

Fentanyl, the active ingredient in Matrifen, is an opioid analgesic presented as a transdermal patch for transdermal use. It provides continuous pain relief for patients with chronic severe pain or cancer‑related pain who require round‑the‑clock opioid therapy.

GNH India supplies Matrifen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to European Union quality standards and provides reliable logistics for global distribution. Our network ensures timely delivery and regulatory support for each market.

Manufacturer / TM Owner

Istituto Gentili S.R.L

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Matrifen (fentanyl) is used in the management of pain conditions that require continuous opioid therapy.

  • Chronic severe pain: provides sustained analgesia for patients with persistent, high‑intensity pain unresponsive to non‑opioid treatments.
  • Cancer pain: controls moderate to severe pain associated with malignant disease, improving quality of life.
  • Chronic non‑cancer pain: offers continuous relief for severe musculoskeletal or neuropathic pain when other therapies have failed.

How It Works

  • Fentanyl is a highly lipophilic synthetic opioid that binds selectively to μ‑opioid receptors in the central nervous system. Activation of these receptors inhibits adenylate cyclase activity, reduces calcium influx, and increases potassium efflux, which together suppress the transmission of nociceptive signals and alter pain perception, resulting in potent analgesia.

Side Effects

Matrifen may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects

  • Nausea
  • Constipation
  • Dizziness
  • Somnolence
  • Dry mouth
  • Application site erythema or itching

Serious or Rare Side Effects

  • Respiratory depression
  • Severe hypotension
  • Opioid dependence or withdrawal syndrome
  • Skin necrosis at the patch site
  • Anaphylactic reaction

Precautions & Warnings

When prescribing Matrifen, clinicians should consider several safety measures.

  • Respiratory assessment: evaluate baseline respiratory function before initiating therapy.
  • Addiction monitoring: watch for signs of opioid dependence or misuse.
  • Dose adjustment: modify dose in patients with renal or hepatic impairment.
  • Concomitant CNS depressants: avoid or use with caution when combined with benzodiazepines or alcohol.
  • Elderly patients: start at the lowest effective dose and monitor closely.
  • Store at room temperature: keep in the original pouch, protect from light and moisture.

Avoid Interactions

Matrifen can interact with other medicines, affecting its safety or efficacy.

Major Interactions (Avoid)

  • Other opioids: additive respiratory depression risk.
  • MAO inhibitors: may cause severe hypotension or serotonin syndrome.
  • CNS depressants (e.g., benzodiazepines): increase sedation and respiratory depression.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): raise fentanyl plasma levels.
  • Respiratory depressants used in anesthesia: potentiate respiratory suppression.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampin): may reduce analgesic effect.
  • Alcohol: can enhance sedation and respiratory depression.
  • Antihistamines: may increase sedation.
  • Diuretics: may affect fluid balance and blood pressure.
  • Certain antidepressants (e.g., SSRIs): monitor for enhanced CNS effects.

Frequently Asked Questions

Matrifen is a fentanyl transdermal patch indicated for the management of chronic severe pain, including cancer‑related pain, in patients who require continuous opioid analgesia when other treatments are inadequate.

Fentanyl is a potent synthetic opioid that binds to μ‑opioid receptors in the central nervous system, inhibiting nociceptive signal transmission and altering pain perception, which produces strong analgesic effects.

The appropriate dose of Matrifen is determined by the prescribing clinician based on the patient’s pain intensity, prior opioid exposure, and clinical condition. Dosing is individualized and the patch strength is selected to deliver a specific amount of fentanyl over a set period, typically 72 hours.

Safety data for fentanyl patches in pregnancy and lactation are limited. Because opioids can cross the placenta and be excreted in breast milk, use is generally discouraged unless the potential benefit justifies the risk. Consultation with a specialist is essential.

To request Matrifen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with oral opioids, the fentanyl patch provides steady plasma concentrations, reducing peaks and troughs that can cause side‑effects. It is more potent than morphine on a milligram‑to‑milligram basis and is suitable for patients who need continuous analgesia and have difficulty swallowing tablets.

Store Matrifen at room temperature, below 25 °C, in its original pouch to protect it from light, moisture and heat. Keep the patch out of reach of children and do not expose it to extreme temperatures or direct sunlight.

The patch is applied to a clean, dry, hair‑free area of the upper torso or upper arm. Press firmly for about 30 seconds, then cover with a protective dressing if needed. Replace the patch according to the prescribed schedule, usually every 72 hours, and dispose of it safely.

The most critical risks include respiratory depression, severe hypotension, profound sedation, opioid dependence and rare skin necrosis at the application site. Patients should be educated to seek immediate medical attention if breathing becomes shallow, they feel unusually drowsy, or the skin shows severe irritation.

Matrifen is contraindicated in patients with known hypersensitivity to fentanyl or other opioids, those with severe respiratory insufficiency, acute or severe asthma, and individuals taking MAO‑inhibitors. Caution is also advised for opioid‑naïve patients, children, and pregnant or breastfeeding women unless benefits outweigh risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Fentanyl

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT